Patients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heightened risk of heart failure — most often within one year of exposure to the chemotherapy treatment, according to a new study. To help identify a patient’s risk for heart failure following the treatment, researchers developed a risk score (0 to 21) based on clinical and echographic variables.
